Edition:
United Kingdom

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

74.84USD
15 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$74.84
Open
--
Day's High
--
Day's Low
--
Volume
1,750
Avg. Vol
2,251,791
52-wk High
$89.53
52-wk Low
$64.27

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $107,268.80
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.53

Financials

  GILD.OQ Industry Sector
P/E (TTM): 8.92 85.68 32.76
EPS (TTM): 9.21 -- --
ROI: 27.00 1.78 14.61
ROE: 63.92 3.28 16.33

UPDATE 2-Long-acting injection a shot in the arm for GSK's HIV business

* GSK hopes to gain market share from market leader Gilead (Updates with latest GSK and Gilead share price moves)

15 Aug 2018

Gilead CEO Milligan, Chairman Martin to step down

Gilead Sciences Inc said on Wednesday that Chief Executive Officer John Milligan and Chairman John Martin will step down as soon as the end of the year, ending a nearly 30-year run at the U.S. biotech company for both men.

25 Jul 2018

UPDATE 4-Gilead CEO Milligan, Chairman Martin to step down

July 25 Gilead Sciences Inc said on Wednesday that Chief Executive Officer John Milligan and Chairman John Martin will step down as soon as the end of the year, ending a nearly 30-year run at the U.S. biotech company for both men.

25 Jul 2018

Gilead CEO Milligan, Chairman Martin to step down

July 25 Gilead Sciences Inc said on Wednesday that Chief Executive Officer John Milligan will step down at the end of the year and that Chairman John Martin will follow soon after, but the biotech did not announce a successor for either man.

25 Jul 2018

GSK's two-drug HIV treatment proves itself in key tests

LONDON GlaxoSmithKline's simple two-drug treatment for HIV works as well as standard triple therapy, even in people with relatively high levels of the virus that causes AIDS, clinical study results presented on Tuesday showed.

24 Jul 2018

GSK's two-drug HIV treatment proves itself in key tests

LONDON GlaxoSmithKline's simple two-drug treatment for HIV works as well as standard triple therapy, even in people with relatively high levels of the virus that causes AIDS, clinical study results presented on Tuesday showed.

24 Jul 2018

GSK's two-drug HIV treatment proves itself in key tests

LONDON, July 24 GlaxoSmithKline's simple two-drug treatment for HIV works as well as standard triple therapy, even in people with relatively high levels of the virus that causes AIDS, clinical study results presented on Tuesday showed.

24 Jul 2018

Rival Novartis, Gilead CAR-T therapies win European panel recommendation

ZURICH Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within months.

29 Jun 2018

CORRECTED-UPDATE 1-Rival Novartis, Gilead CAR-T therapies win European panel recommendation

ZURICH, June 29 Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within months.

29 Jun 2018

Rival Novartis, Gilead CAR-T therapies win European panel recommendation

Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within a couple of months.

29 Jun 2018

Earnings vs. Estimates